Brighter AB (publ) announced that in the Actiste clinical-research - being conducted in partnership with the Northern Care Alliance NHS Foundation Trust in the UK city of Salford - the first patient has been recruited and started to use Actiste. The patient will continue to use Actiste for the next six months to check blood glucose and administer insulin and being an IoT device, Actiste automatically records this data. Additional clinically relevant information like meals and physical activity in connection to blood glucose measurements and actual injected insulin dose can be tagged on Actiste and can provide an opportunity for the report to be shared with the clinical-research team at Salford Royal Hospital.

The patient will also use the Companion app for additional insights about real-life diabetes management. Later this year the results of the full study - including 35 patients with type 1 diabetes and 35 patients with insulin-treated type 2 diabetes - will be analyzed and study publication will be shared with the diabetes scientific community. The aim is to further verify the potential benefits of Actiste in managing type 1 and type 2 insulin-treated diabetes and compare it vs the standard of care.